Abound Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Abound Wealth Management's BMY Position: Q2 2026 in Review
Abound Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 16% in Q2 2026, selling an estimated $20.2K and leaving 1,791 shares worth $103K. The position accounts for 0.02% of the portfolio, ranked #157.
Abound Wealth Management first reported a position in BMY in Q3 2022 and has held it in 16 quarters since. The position peaked at $130K in Q1 2026. 812 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Abound Wealth Management held 1,791 shares of Bristol-Myers Squibb worth $103K as of Q2 2026.
- Abound Wealth Management sold 351 Bristol-Myers Squibb shares in Q2 2026, an estimated $20.2K.
- Bristol-Myers Squibb made up 0.02% of Abound Wealth Management's portfolio in Q2 2026, its #157 holding.
- Abound Wealth Management first reported a position in Bristol-Myers Squibb in Q3 2022 and has held it in 16 quarters since.
- Abound Wealth Management's Bristol-Myers Squibb position peaked at $130K in Q1 2026.
- 812 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.